i including their pharmaceutically acceptable salts are useful in the treatment of physiological conditions in which angiotensin converting enzyme inhibitors have been shown to be useful such conditions include disease states characterized by abnormalities in blood pressure intraocular pressure and renin including cardiovascular diseases particularly hypertension and congestire heart failure glaucoma and renal diseases such as renal failure the dual inhibitors are also useful in the treatment of physiological conditions in which neutral endopeptidase inhibitors have been shown to be useful such conditions also include cardiovascular diseases particularly hypertension hyperaldosteronemia renal diseases glaucoma as well as the relief of acute or chronic pain thus the compounds of formula i are useful in reducing blood pressure and the dual inhibitors of formula i are additionally useful for this purpose due to their diuresis and natriuresis properties the compounds of formula i including their pharmaceutically acceptable salts can be administered for these effects to a mammalian host such as man at from about 1 mg to about 100 mg per kg of body weight per day preferably from about 1 mg to about 50 mg per kg of body weight per day the compounds of formula i are preferably administered orally but parenteral routes such as subcutaneous intramuscular and intravenous can also be employed as can topical routes of administration the daily dose can be administered singly or can be divided into two to four doses administered throughout the day the inhibitors of formula i can be administered in combination with human anf 99 126 such combination would contain the inhibitor of formula i at from about 1 to about 100 mg per kg.